Hepatitis B Surface Antibody

You probably got the hepatitis B vaccine years ago and never thought about it again. The question this test answers is simple: did the protection actually stick, and is it still there now? Hepatitis B is one of the few viruses where you can know, with a single blood draw, whether your immune system is ready for it.

This becomes more than academic if you travel to high-prevalence regions, work in healthcare, are about to start treatment that suppresses your immune system, or have a partner or household member who is infected. Knowing your number turns a vague hope into a yes or no.

What This Antibody Actually Is

Anti-HBs (hepatitis B surface antibody) is an immune protein your body makes against the outer envelope of the hepatitis B virus. You can develop it in two ways: by responding to the vaccine, or by clearing a real infection. Either way, having it in your blood means your immune system has learned to recognize and neutralize the virus before it can take hold in your liver.

It is produced by specialized white blood cells (B cells and the plasma cells they become) that remember the virus's surface protein. When you encounter hepatitis B later, these cells can ramp up antibody production quickly, which is why people who once tested protective often stay protected even when their measurable antibody level drops over the years.

What the Number Means

A level at or above 10 mIU/mL is widely treated as the threshold for protective immunity in vaccinated adults, children, and blood donors. In a large study of Japanese blood donors followed for nearly five years, no new hepatitis B infections occurred in people with anti-HBs at or above this protective threshold. That is about as clear an outcome signal as serology gets.

Below that, the picture gets more nuanced. A low or undetectable level after a successful past response does not necessarily mean you have lost protection. A 30-year follow-up of Alaska Native adults and children showed that the large majority of previously vaccinated people produced a strong booster response even decades later, indicating that immune memory persists even when circulating antibody fades. A separate cohort showed cellular immunity to hepatitis B surface antigen lasting at least 32 years after the original shots, regardless of whether the antibody itself was still detectable.

Reading This Test in Context

Anti-HBs is one of three core hepatitis B blood markers. The other two are surface antigen (HBsAg, a piece of the virus itself) and core antibody (anti-HBc, another antibody made during real infection but not from vaccination). Reading them together is how the test earns its real value. A positive anti-HBs alone usually points to vaccine-induced immunity. Positive anti-HBs alongside positive anti-HBc points to past infection that you cleared. Positive surface antigen with negative anti-HBs points to ongoing infection.

The combinations get more complicated than they first appear. A minority of people with chronic hepatitis B test positive for both surface antigen and anti-HBs at the same time, which sounds contradictory but is not rare and does not necessarily mean a lab error. In children with chronic hepatitis B, this coexistence pattern was associated with better outcomes during antiviral treatment, including higher rates of clearing the surface antigen and the e antigen.

Why Your Standard Panel Is Not Enough

A routine liver panel does not tell you whether you are protected against hepatitis B. Normal ALT (alanine aminotransferase, a liver enzyme), normal AST, and normal bilirubin can all coexist with no immunity at all, or with an active infection that has not yet damaged the liver enough to show up. The hepatitis B surface antigen test, the one usually ordered first to screen for infection, also misses people who quietly carry low-level virus without producing detectable antigen, a state called occult infection.

This is why anti-HBs has a specific role: it answers the protection question that no other common test answers. United States Preventive Services Task Force guidance recommends hepatitis B screening in adolescents and adults at increased risk. The added information from anti-HBs is what tells you whether you need another vaccine series, a booster, or nothing at all.

Immunity After Vaccination

Most people who complete the standard hepatitis B vaccine series develop protective anti-HBs levels. Real-world studies show high seroprotection rates in vaccinated healthcare workers, infants, and medical interns vaccinated in childhood. But not everyone responds the same way, and the level you develop tends to drift down over time.

A study following children vaccinated at 2, 4, 6, and 18 months found that the proportion still maintaining protective levels by age seven depended on the vaccine type used. People with chronic kidney disease, HIV, type 2 diabetes, or who are on long-term immune-suppressing medication often respond more weakly to the vaccine and need higher doses, more doses, or revaccination.

Reactivation Risk in Immunosuppression

If you have ever been exposed to hepatitis B (positive anti-HBc) and you are about to start chemotherapy, a B-cell-depleting drug like rituximab, a biologic for an autoimmune condition, or a stem-cell transplant, the virus can wake up. This is called reactivation, and it can be dangerous.

A meta-analysis of patients with resolved hepatitis B infection receiving chemotherapy for blood cancers found that having anti-HBs was associated with substantially lower reactivation rates compared to anti-HBs-negative patients. In a prospective study of patients on biologic therapy for rheumatic disease, hepatitis B DNA was detected more often in people with no anti-HBs or low titers, and reactivation occurred only in people whose anti-HBs went negative.

If you are heading into immunosuppression, knowing your anti-HBs level helps your care team decide whether to monitor you, give antiviral prophylaxis, or boost your vaccine response before starting treatment.

Mortality Signal in Resolved Infection

In a United States population-based cohort of adults with resolved hepatitis B infection, anti-HBs-negative status was associated with higher risk of death from all causes and from cancer compared with anti-HBs-positive status. This finding does not establish that the antibody itself prevents death, but it does suggest that the presence of a working antibody response is a marker of more complete immune control.

Blood Donation and Occult Infection

In the Japanese blood donor study mentioned earlier, protective anti-HBs levels were associated with no new infections, but the same dataset also identified people with so-called occult hepatitis B, where the virus is present at very low levels even though the standard surface antigen test is negative. Some of these donors had anti-HBs and some did not. The implication is straightforward: anti-HBs is a strong protection signal for the person carrying it, but it is not a perfect guarantee that someone cannot still harbor low-level virus.

Reconciling the Paradox

You will see two facts in this article that look like they fight each other. One: protection requires a measurable circulating antibody. Two: people whose levels fall below the protective cutoff often remain fully protected. Both are true, and they make sense together once you separate two ideas. The first idea is the antibody currently circulating in your blood, which can wane. The second is the immune memory stored in long-lived B cells, which generally does not. After a confirmed past response, a falling number is not the same as losing immunity. The number tracks the antibody, not the memory behind it. This is why a low number is not automatically a problem if you previously responded well, and why a single reading is best interpreted alongside your vaccination and infection history.

Tracking Your Trend

A single anti-HBs number is most useful as a starting point. If you are confirmed protective after vaccination, you usually do not need frequent retesting. But there are situations where serial testing is genuinely useful: before starting an immunosuppressive medication, after a known exposure, periodically if you work in a high-risk environment, and during long-term follow-up of chronic hepatitis B treatment to see if you are moving toward functional cure (loss of surface antigen with development of anti-HBs).

A reasonable cadence: get a baseline now if you have never been tested, retest in 3 to 6 months if you have just completed a vaccine series or booster, and then on an as-needed basis driven by life events, exposures, or planned immunosuppression. For people in occupational or healthcare settings, annual or biennial checks make sense.

What to Do With an Unexpected Result

If your anti-HBs comes back below the protective level and you have never had the vaccine or are not sure, the next step is usually a full hepatitis B panel: surface antigen and core antibody alongside anti-HBs. This three-test view tells you whether you are unprotected and uninfected (vaccinate), protected and previously infected (no action needed), or actively infected (further workup and likely a hepatologist or infectious disease specialist).

If you previously responded to vaccination and now show low or undetectable antibody, the practical move is to discuss a booster with a clinician, especially if you have an upcoming exposure risk. If you are about to start immune-suppressing therapy and the panel shows past exposure, that is a conversation with your treating physician about antiviral prophylaxis. Hepatitis B DNA testing is the next step if there is any suspicion of active or occult infection.

When Results Can Be Misleading

• Recent vaccination: anti-HBs rises in the weeks after a vaccine dose, so testing too soon can either over- or underestimate your steady-state immunity. Wait at least one to two months after the final dose for a meaningful read.
• Immune-suppressing medications: rituximab and other B-cell-depleting drugs can lower anti-HBs titers, with one prospective study showing a meaningful decline over about five and a half months. This is a real change in your protection, not a measurement glitch, and it matters because reactivation risk rises as the antibody falls.
• Corticosteroid courses: in people with previous hepatitis B exposure, high peak daily prednisolone doses can trigger hepatitis flares and surface antigen reappearance. The antibody itself is not artifactually altered, but the serologic picture can shift while you are on high-dose steroids.
• Occult infection: in rare cases, you can have detectable anti-HBs and still carry low-level hepatitis B DNA. The antibody is real, but it does not always tell the full story without DNA testing.

How This Test Is Collected

This is a standard venous blood draw, no fasting needed, no time-of-day requirement. Most labs report anti-HBs in mIU/mL. There is no special preparation. If you have been recently vaccinated, note the date for your record so the result can be interpreted in context.